Shira Sherman

Shira Sherman

Auto-generated profile, based on publicly available information

Shira Sherman

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
FHFrancisco Hermida
Francisco Hermida
YXYingtian Xie
Yingtian Xie
SSShira Sherman
Shira Sherman
ZNZsuzsanna Nagy
Zsuzsanna Nagy
DRDouglas Russo
Douglas Russo
RJRinath Jeselsohn
Rinath Jeselsohn
Immunotherapies have yet to demonstrate significant efficacy in the treatment of hormone receptor–positive (HR+) breast cancer. Given that endocrine therapy (ET) is the primary approach for treating HR+ breast cancer, we investigated the effects of ET on the tumor immune microenvironment (TME) in HR+ breast cancer. Spatial proteomics of primary HR+ breast cancer samples obtained at baseline and after ET from patients enrolled in a neoadjuvant clinical trial (NCT02764541) indicated that ET upregulated β2-microglobulin and influenced the TME in a manner that promotes enhanced immunogenicity. To gain a deeper understanding of the underlying mechanisms, the intrinsic effects of ET on cancer cells were explored, which revealed that ET plays a crucial role in facilitating the chromatin binding of RelA, a key component of the NF-κB complex. Consequently, heightened NF-κB signaling enhanced the response to interferon-gamma, leading to the upregulation of β2-microglobulin and other antigen presentation-related genes. Further, modulation of NF-κB signaling using a SMAC mimetic in conjunction with ET augmented T-cell migration and enhanced MHC-I-specific T-cell–mediated cytotoxicity. Remarkably, the combination of ET and SMAC mimetics, which also blocks prosurvival effects of NF-κB signaling through the degradation of inhibitors of apoptosis proteins, elicited tumor regression through cell autonomous mechanisms, providing additional support for their combined use in HR+ breast cancer. Significance: Adding SMAC mimetics to endocrine therapy enhances tumor regression in a cell autonomous manner while increasing tumor immunogenicity, indicating that this combination could be an effective treatment for HR+ patients with breast cancer.

8 June 2024 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
AGAlbert Grinshpun
Albert Grinshpun
DRDouglas Russo
Douglas Russo
WMWen Ma
Wen Ma
AVAna Verma
Ana Verma
FHFrancisco Hermida-Prado
Francisco Hermida-Prado
RJRinath Jeselsohn
Rinath Jeselsohn
The ESR1 ligand binding domain activating mutations are the most prevalent genetic mechanism of acquired endocrine resistance in metastatic hormone receptor-positive breast cancer. These mutations confer endocrine resistance that remains estrogen receptor (ER) dependent. We hypothesized that in the presence of the ER mutations, continued ER blockade with endocrine therapies that target mutant ER is essential for tumor suppression even with chemotherapy treatment. Here, we conducted comprehensive pre-clinical in vitro and in vivo experiments testing the efficacy of adding fulvestrant to fluorouracil (5FU) and the 5FU pro-drug, capecitabine, in models of wild-type (WT) and mutant ER. Our findings revealed that while this combination had an additive effect in the presence of WT-ER, in the presence of the Y537S ER mutation there was synergy. Notably, these effects were not seen with the combination of 5FU and selective estrogen receptor modulators, such as tamoxifen, or in the absence of intact P53. Likewise, in a patient-derived xenograft (PDX) harboring a Y537S ER mutation the addition of fulvestrant to capecitabine potentiated tumor suppression. Moreover, multiplex immunofluorescence revealed that this effect was due to decreased cell proliferation in all cells expressing ER and was not dependent on the degree of ER expression. Taken together, these results support the clinical investigation of the combination of ER antagonists with capecitabine in patients with metastatic hormone receptor-positive breast cancer who have experienced progression on endocrine therapy and targeted therapies, particularly in the presence of an ESR1 activating mutation.

24 November 2025
Verified
Other
Open access
FHFrancisco Hermida
Francisco Hermida
YXYingtian Xie
Yingtian Xie
SSShira Sherman
Shira Sherman
ZNZsuzsanna Nagy
Zsuzsanna Nagy
DRDouglas Russo
Douglas Russo
RJRinath Jeselsohn
Rinath Jeselsohn
Supplementary Fig. S5. Analysis of the impact of the ER axis on the response to IFNg stimulation in HR+ breast cancer cells.

24 November 2025
Verified
Other
Open access
FHFrancisco Hermida
Francisco Hermida
YXYingtian Xie
Yingtian Xie
SSShira Sherman
Shira Sherman
ZNZsuzsanna Nagy
Zsuzsanna Nagy
DRDouglas Russo
Douglas Russo
RJRinath Jeselsohn
Rinath Jeselsohn
Supplementary Fig. S7. Impact of treatment with fulvestrant, birinapant, and their combination on a PDX model of HR+ breast cancer.


24 November 2025
Verified
Other
Open access
FHFrancisco Hermida
Francisco Hermida
YXYingtian Xie
Yingtian Xie
SSShira Sherman
Shira Sherman
ZNZsuzsanna Nagy
Zsuzsanna Nagy
DRDouglas Russo
Douglas Russo
RJRinath Jeselsohn
Rinath Jeselsohn
Supplementary Fig. S2. Comprehensive analysis of protein expression changes before and after endocrine treatment